Roche Tecentriq + tyrosine kinase inhibitor fails in NSCLCDecember 09, 2022 - Metastatic non-small cell lung cancer (NSCLC) marks the latest in a string of clinical losses for the pairing of Exelixis and Ipsen's tyrosine kinase inhibitor Cabometyx and Roche’s immuno-oncology star Tecentriq.
To succeed the combo needed to show it could help patients live longer than chemotherapy alone.
The results are a blow not just to Roche and Ipsen, but also Takeda and Exelixis, the original developer of Cabometyx.
[ In July 2022 Takeda cut ties with Turnstone Biologics, the OV developer of the monkeypox (Mpox) vaccina virus.]
This isn’t the first time the Roche and Ipsen combo has stumbled this year. Back in March, Cabometyx and Tecentriq dropped the ball in a phase 3 study against Bayer’s Nexavar in newly-diagnosed liver cancer.
https://www.fiercepharma.com/pharma/tecentriq-and-cabometyx-flunk-lung-cancer-study-damning-roche-ipsen-combo-indication-analyst
Whereas Roche's Tecentriq + ONCY's pelareorep proves effective in pancreatic cancer as demonstrated in ONCY' Phase II Goblet clinical trial with a 69% ORR and a 65% Clinical Benefit Rate (CBR).
https://ir.oncolyticsbiotech.com/press-releases/detail/586/oncolytics-biotech-presents-updated-clinical-data-at-sitc